Cenegermin
Sponsors
Dompe' Farmaceutici S.p.A., Dompé Farmaceutici S.p.A
Conditions
Dry Eye DiseaseNon-Arteritic Anterior Ischemic Optic NeuropathyNon-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Persistent Corneal Epithelial DefectSpastic Cerebral PalsySubacute Moderate to Severe Traumatic Brain Injury (TBI)
Phase 2
Randomized, Double-Blinded, Vehicle-Controlled, Crossover Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Pediatric Participants with Spastic Cerebral Palsy (CP).
Not yet recruitingCTIS2025-522786-29-00
Target: 60Updated: 2025-12-17
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
Not yet recruitingCTIS2025-522692-29-00
Target: 98Updated: 2026-04-15
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Not yet recruitingCTIS2025-524748-37-00
Target: 156Updated: 2026-09-04
Phase 3
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
CompletedNCT05136170
Start: 2022-01-27End: 2023-05-24Updated: 2025-11-26
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
RecruitingNCT07453888
Start: 2026-07-01End: 2027-09-01Target: 272Updated: 2026-09-10
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
RecruitingNCT07519902
Start: 2026-06-02End: 2027-12-01Target: 150Updated: 2026-07-16